| Valeant Pharmaceuticals International, Inc. - VRX.t is a pharmaceutical company that offers a diverse product portfolio with focus on branded pharmaceuticals, branded generics and over-the-counter products. |  |
Valeant Pharmaceuticals International, Inc. today announced its fourth-quarter and full-year 2017 financial results.
Fourth-Quarter 2017 Financial Results
Revenues of $2.163 Billion
GAAP Net Income of $513 Million
GAAP Cash Flow from Operations of $578 Million
Adjusted EBITDA (non-GAAP) of $875 Million
Full-Year 2017 Financial Results
$8.724 Billion
GAAP Net Income of $2.404 Billion
GAAP Cash Flow from Operations of $2.290 Billion
Adjusted EBITDA (non-GAAP) of $3.638 Billion
    |
    |    
|    |
